Blocking interleukin-1 in rheumatic diseases: Its initial disappointments and recent successes in the treatment of autoinflammatory diseases

Annals of the New York Academy of Sciences

Volumn 1182, Issue , 2009, Pages 111-123

  Goldbach Mansky, Raphaela ^a  

^a NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES   (United States)

Author keywords

Anakinra; Autoinflammatory diseases; Chronic inflammatory neurologic, cutaneous and arthritis syndrome (CINCA); Deficiency of the IL 1 receptor antagonist (DIRA); Genetic disease; IL 1Ra; IL1RN; Interleukin (IL ) 1; Neonatal disorder; Neonatal onset multisystem inflammatory disease (NOMID); NLRP3

Indexed keywords

ALPHA INTERFERON; AZITHROMYCIN; BISPHOSPHONIC ACID DERIVATIVE; CANAKINUMAB; COLCHICINE; CORTICOSTEROID DERIVATIVE; CYCLOSPORIN; DISEASE MODIFYING ANTIRHEUMATIC DRUG; ETANERCEPT; INTERLEUKIN 1; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; LEFLUNOMIDE; METHOTREXATE; NONSTEROID ANTIINFLAMMATORY AGENT; PLACEBO; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; RILONACEPT; STEROID; THALIDOMIDE; TUMOR NECROSIS FACTOR INHIBITOR;

ARTHRITIS; AUTOIMMUNE DISEASE; AUTOINFLAMMATORY DISEASE; BACTERIAL PNEUMONIA; BEHCET DISEASE; CELLULITIS; CINCA SYNDROME; CLINICAL TRIAL; CONFERENCE PAPER; DRUG APPROVAL; DRUG EFFICACY; DRUG HALF LIFE; DRUG MECHANISM; DRUG RECEPTOR BINDING; DRUG SAFETY; DRUG TOLERABILITY; FAMILIAL COLD AUTOINFLAMMATORY SYNDROME; FAMILIAL MEDITERRANEAN FEVER; FIBROUS DYSPLASIA; FOOD AND DRUG ADMINISTRATION; GENE MUTATION; GOUT; HUMAN; HYPERIMMUNOGLOBULINEMIA D AND PERIODIC FEVER SYNDROME; INFECTIOUS ARTHRITIS; INJECTION SITE REACTION; JUVENILE RHEUMATOID ARTHRITIS; LOADING DRUG DOSE; MAJEED SYNDROME; MUCKLE WELLS SYNDROME; MYCOBACTERIOSIS; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PAPA SYNDROME; PEDIATRIC GRANULOMATOUS ARTHRITIS; PNEUMONIA; PSEUDOGOUT; RHEUMATIC DISEASE; RHEUMATOID ARTHRITIS; SCHNITZLER SYNDROME; SEPSIS; TREATMENT OUTCOME; TREATMENT RESPONSE; TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED PERIODIC SYNDROME; VERTIGO;

EID: 73849134001     PISSN: 00778923     EISSN: 17496632     Source Type: Book Series    
DOI: 10.1111/j.1749-6632.2009.05159.x     Document Type: Conference Paper

References (55)

1. Balavoine, J.F., B. De Rochemonteix, K.Williamson, et al. 1986. Prostaglandin E2 and collagenase production by fibroblasts and synovial cells is regulated by urine-derived human interleukin 1 and inhibitor(s). J. Clin. Invest. 78: 1120-1124. (Pubitemid 17177097)
2. Hannum, C.H., C.J. Wilcox, W.P. Arend, et al. 1990. Interleukin-1 receptor antagonist activity of a human interleukin-1 inhibitor. Nature 343: 336-340.
3. Dinarello, C.A. 1996. Biologic basis for interleukin-1 in disease. Blood 87: 2095-2147.
4. Arend, W.P. 2002. The balance between IL-1 and IL-1Ra in disease. Cytokine Growth Factor Rev. 13: 323-340.
5. Petrilli, V., C. Dostert, D.A. Muruve & J. Tschopp. 2007. The inflammasome: A danger sensing complex triggering innate immunity. Curr. Opin. Immunol. 19: 615-622.
6. Hacham, M., S. Argov, R.M. White, et al. 2000. Distinct patterns of IL-1 alpha and IL-1 beta organ distribution-a possible basis for organ mechanisms of innate immunity. Adv. Exp. Med. Biol. 479: 185-202.
7. Cain, B.S., D.R. Meldrum, A.H. Harken & R.C. Mcintyre, Jr. 1998. The physiologic basis for anticytokine clinical trials in the treatment of sepsis. J. Am. Coll. Surg. 186: 337-350.
8. Smolen, J.S.,D. Aletaha,M.Koeller, et al. 2007. New therapies for treatment of rheumatoid arthritis. Lancet 370: 1861-1874.
9. O'Dell, J.R. 2004. Therapeutic strategies for rheumatoid arthritis. N. Engl. J. Med. 350: 2591-2602.
10. Glaser, R.L. & R. Goldbach-Mansky. 2008. The spectrum of monogenic autoinflammatory syndromes: Understanding disease mechanisms and use of targeted therapies. Curr. Allergy Asthma Rep. 8: 288-298.
11. Hoffman, H.M., J.L. Mueller, D.H. Broide, et al. 2001. Mutation of a new gene encoding a putative pyrin-like protein causes familial cold autoinflammatory syndrome and Muckle-Wells syndrome. Nat. Genet. 29: 301-305.
12. Aksentijevich, I., M. Nowak, M. Mallah, et al. 2002. De novo CIAS1 mutations, cytokine activation, and evidence for genetic heterogeneity in patients with neonatal-onset multisystem inflammatory disease (NOMID): A new member of the expanding family of pyrin-associated autoinflammatory diseases. Arthritis Rheum. 46: 3340-3348.
13. Feldmann, J., A.M. Prieur, P. Quartier, et al. 2002. Chronic infantile neurological cutaneous and articular syndrome is caused by mutations in CIAS1, a gene highly expressed in polymorphonuclear cells and chondrocytes. Am. J. Hum. Genet. 71: 198-203.
14. Aksentijevich, I., S.L. Masters, P.J. Ferguson, et al. 2009. An autoinflammatory disease with deficiency of the interleukin-1-receptor antagonist. N. Engl. J. Med. 360: 2426-2437.
15. Reddy, S., S. Jia, R. Geoffrey, et al. 2009. An autoinflammatory disease due to homozygous deletion of the IL1RN locus. N. Engl. J. Med. 360: 2438-2444.
16. Prieur, A.M., C. Griscelli, F. Lampert, et al. 1987. A chronic, infantile, neurological, cutaneous and articular (CINCA) syndrome. A specific entity analysed in 30 patients. Scand. J. Rheumatol. Suppl. 66: 57-68.
17. Goldbach-Mansky, R., N.J. Dailey, S.W. Canna, et al. 2006. Neonatal-onset multisystem inflammatory disease responsive to interleukin-1beta inhibition. N. Engl. J. Med. 355: 581-592.
18. Goldbach-Mansky, R., S.D. Shroff, M. Wilson, et al. 2008. A pilot study to evaluate the safety and efficacy of the long-acting interleukin-1 inhibitor rilonacept (interleukin-1 Trap) in patients with familial cold autoinflammatory syndrome. Arthritis Rheum. 58: 2432-2442.
19. Hoffman, H.M., M.L. Throne, N.J. Amar, et al. 2008. Efficacy and safety of rilonacept (interleukin-1 Trap) in patients with cryopyrin-associated periodic syndromes: Results from two sequential placebocontrolled studies. Arthritis Rheum. 58: 2443-2452.
20. Lachmann, H.J., I. Kone-Paut, J.B. Kuemmerle-Deschner, et al. 2009. Use of canakinumab in the cryopyrin-associated periodic syndrome. N. Engl. J. Med. 360: 2416-2425.
21. Fisher, C.J., Jr., G.J. Slotman, S.M. Opal, et al. 1994. Initial evaluation of human recombinant interleukin-1 receptor antagonist in the treatment of sepsis syndrome: A randomized, open-label, placebocontrolled multicenter trial. Crit. Care Med. 22: 12-21.
22. Fisher, C.J., Jr., J.F. Dhainaut, S.M. Opal, et al. 1994. Recombinant human interleukin 1 receptor antagonist in the treatment of patients with sepsis syndrome. Results from a randomized, double-blind, placebocontrolled trial. Phase III rhIL-1ra Sepsis Syndrome Study Group. JAMA 271: 1836-1843.
23. Bresnihan, B., J.M. Alvaro-Gracia, M. Cobby, et al. 1998. Treatment of rheumatoid arthritis with recombinant human interleukin-1 receptor antagonist. Arthritis Rheum. 41: 2196-2204.
24. Jiang, Y., H.K. Genant, I. Watt, et al. 2000. A multicenter, double-blind, dose-ranging, randomized, placebo-controlled study of recombinant human interleukin-1 receptor antagonist in patients with rheumatoid arthritis: Radiologic progression and correlation of Genant and Larsen scores. Arthritis Rheum. 43: 1001-1009.
25. Cohen, S., E. Hurd, J. Cush, et al. 2002. Treatment of rheumatoid arthritis with anakinra, a recombinant human interleukin-1 receptor antagonist, in combination with methotrexate: Results of a twenty-four-week, multicenter, randomized, doubleblind, placebo-controlled trial. Arthritis Rheum. 46: 614-624.
26. Cohen, S.B., L.W. Moreland, J.J. Cush, et al. 2004. A multicentre, double blind, randomised, placebo controlled trial of anakinra (Kineret), a recombinant interleukin 1 receptor antagonist, in patients with rheumatoid arthritis treated with background methotrexate. Ann. Rheum. Dis. 63: 1062-1068.
27. Fleischmann, R.M., J. Schechtman, R. Bennett, et al. 2003. Anakinra, a recombinant human interleukin-1 receptor antagonist (r-metHuIL-1ra), in patients with rheumatoid arthritis: A large, international, multicenter, placebo-controlled trial. Arthritis Rheum. 48: 927-934.
28. Fleischmann, R.M., J.Tesser, M.H. Schiff, et al. 2006. Safety of extended treatment with anakinra in patients with rheumatoid arthritis. Ann. Rheum. Dis. 65: 1006-1012. (Pubitemid 44133261)
29. Gattringer, R.,H. Lagler, K.B.Gattringer, et al. 2007. Anakinra in two adolescent female patients suffering from colchicine-resistant familial Mediterranean fever: Effective but risky. Eur. J. Clin. Invest. 37: 912-914.
30. Kuijk, L.M., A.M. Govers, J. Frenkel &W.J. Hofhuis. 2007. Effective treatment of a colchicine-resistant familial Mediterranean fever patient with anakinra. Ann. Rheum. Dis. 66: 1545-1546.
31. Roldan, R., A.M. Ruiz, M.D. Miranda & E. Collantes. 2008. Anakinra: new therapeutic approach in children with FamilialMediterranean Fever resistant to colchicine. Joint Bone Spine 75: 504-505.
32. Simon, A., E.J. Bodar, J.C. Van Der Hilst, et al. 2004. Beneficial response to interleukin 1 receptor antagonist in traps. Am. J. Med. 117: 208-210. (Pubitemid 39055877)
33. Gattorno, M., M.A. Pelagatti, A. Meini, et al. 2008. Persistent efficacy of anakinra in patients with tumor necrosis factor receptor-associated periodic syndrome. Arthritis Rheum. 58: 1516-1520.
34. Sacre, K., B. Brihaye,O. Lidove, et al. 2008. Dramatic improvement following interleukin 1beta blockade in tumor necrosis factor receptor-1-associated syndrome (TRAPS) resistant to anti-TNF-alpha therapy. J. Rheumatol. 35: 357-358.
35. Bodar, E.J., J.C.Van DerHilst, J.P. Drenth, et al. 2005. Effect of etanercept and anakinra on inflammatory attacks in the hyper-IgD syndrome: introducing a vaccination provocation model.Neth. J.Med. 63: 260-264.
36. Cailliez, M., F. Garaix, C. Rousset-Rouviere, et al. 2006. Anakinra is safe and effective in controlling hyperimmunoglobulinaemia D syndrome-associated febrile crisis. J. Inherit. Metab. Dis. 29: 763.
37. Hoffman, H.M., S. Rosengren, D.L. Boyle, et al. 2004. Prevention of cold-associated acute inflammation in familial cold autoinflammatory syndrome by interleukin-1 receptor antagonist. Lancet 364: 1779-1785.
38. Arostegui, J.I., C. Arnal, R. Merino, et al. 2007. NOD2 gene-associated pediatric granulomatous arthritis: Clinical diversity, novel and recurrent mutations, and evidence of clinical improvement with interleukin-1 blockade in a Spanish cohort. Arthritis Rheum. 56: 3805-3813.
39. Dierselhuis, M.P., J. Frenkel, N.M. Wulffraat & J.J. Boelens. 2005. Anakinra for flares of pyogenic arthritis in PAPA syndrome. Rheumatology (Oxford) 44: 406-408.
40. Reiff, A. 2005. The use of anakinra in juvenile arthritis. Curr. Rheumatol. Rep. 7: 434-440.
41. Pascual, V., F. Allantaz, E. Arce, et al. 2005. Role of interleukin-1 (IL-1) in the pathogenesis of systemic onset juvenile idiopathic arthritis and clinical response to IL-1 blockade. J. Exp. Med. 201: 1479-1486.
42. Gattorno, M., A. Piccini, D. Lasiglie, et al. 2008. The pattern of response to anti-interleukin-1 treatment distinguishes two subsets of patients with systemiconset juvenile idiopathic arthritis. Arthritis Rheum. 58: 1505-1515.
43. Lequerre, T., P. Quartier, D. Rosellini, et al. 2008. Interleukin-1 receptor antagonist (anakinra) treatment in patients with systemic-onset juvenile idiopathic arthritis or adult onset Still disease: preliminary experience in France. Ann. Rheum. Dis. 67: 302-308.
44. Quartier, P. 2008. [Still's disease (Systemic-Onset Juvenile Idiopathic Arthritis)]. Arch. Pediatr. 15: 865-866.
45. Lovell, D.J., N. Ruperto, S. Goodman, et al. 2008. Adalimumab with or without methotrexate in juvenile rheumatoid arthritis. N. Engl. J. Med. 359: 810-820.
46. Lequerre, T., P. Quartier, D. Rosellini, et al. 2008. Interleukin-1 receptor antagonist (anakinra) treatment in patients with systemic-onset juvenile idiopathic arthritis or adult onset Still disease: preliminary experience in France. Ann. Rheum. Dis. 67: 302-308.
47. Fitzgerald, A.A., S.A. Leclercq, A. Yan, et al. 2005. Rapid responses to anakinra in patients with refractory adult-onset Still's disease. Arthritis Rheum. 52: 1794-1803.
48. Vasques Godinho, F.M., M.J. Parreira Santos & D.S. Canas. 2005. Refractory adult onset Still's disease successfully treated with anakinra. Ann. Rheum. Dis. 64: 647-648.
49. So, A., T. De Smedt, S. Revaz & J. Tschopp. 2007. A pilot study of IL-1 inhibition by anakinra in acute gout. Arthritis Res. Ther. 9: R28.
50. McGonagle, D., A.L. Tan, S. Shankaranarayana, et al. 2007. Management of treatment resistant inflammation of acute on chronic tophaceous gout with anakinra. Ann. Rheum. Dis. 66: 1683-1684.
51. Botsios, C., P. Sfriso, A. Furlan, et al. 2008. Resistant Behcet disease responsive to anakinra. Ann. Intern. Med. 149: 284-286.
52. Larsen, C.M., M. Faulenbach, A. Vaag, et al. 2007. Interleukin-1-receptor antagonist in type 2 diabetes mellitus. N. Engl. J. Med. 356: 1517-1526.
53. Anakinra package insert: http://www.kineretrx. com/professional/pi.jsp
54. Rilonacept package insert: http://www.regeneron. com/ARCALYST-fpi.pdf
55. Canakinumab package insert: http://www.pharma. us.novartis.com/products/ name/ilaris.jsp